Companies Dominating the Erythropoietin Drugs Landscape
- AstraZeneca PLC
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Amgen, Inc.
- Biocon Limited
- Celltrion, Inc.
- Dr. Reddy’s Laboratories Ltd.
- F. Hoffmann-La Roche Ltd.
- Intas Pharmaceuticals Ltd.
- Johnson & Johnson
- Kyowa Kirin Co., Ltd.
- LG Chem, Ltd.
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Genexine
Major key players continuously invest in research and development to improve the effectiveness, safety, and delivery methods of EPO drugs. Partnerships with hospitals, clinics, and distribution networks help key players reach a wider audience. Collaborations with local healthcare providers or joint ventures with local manufacturers enable global companies to leverage regional expertise, boost local production, and improve drug availability.
Here are some key players in the erythropoietin drugs market:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Erythropoietin Drugs Market in 2025 is assessed at USD 11.37 billion.
The global market size was worth around USD 10.95 billion in 2024 and is set to register a CAGR of more than 4.8%, exceeding USD 20.14 billion revenue by 2037.
North America is expected to total USD 5.36 billion by 2037, due to the high prevalence rates of chronic CKD and cancer, which often result in anemia.
The major players in the market include Amgen, Inc., Biocon Limited, Celltrion, Inc., Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche Ltd., Intas Pharmaceuticals Ltd., Johnson & Johnson, Kyowa Kirin Co., Ltd, and others.
